Canine’s Corner

Treat The Dawgs Well

Dr.Scott Rocklage Paving the Way into Cures of the Future

Dr. Scott Rocklage is a managing partner of 5 AM Ventures. The Managing Partner of 5 AM Ventures has over twenty years of experience successfully leading Health Care related companies to greater heights. His impressive leadership qualities have seen him ensure the approval of many drug applications by the FDA. Under his guidance, many more drugs have been put into clinical trials with high potential at getting into the market to help the ailing people in society. Dr. Scott Rocklage has served many different companies at various levels where his expertise was needed. Among his career accomplishments include serving as the head of many organizations with a worldwide reputation in the pharmaceutical industry. The doctor holds a Master’s Degree in Science, Chemistry from MIT and a Bachelor’s of the same from California University. Learn more:


In an article by Medical Daily Times, we get to have a glimpse at the great works done by Dr. Scott Rocklage and his team experts. The chairman of the Board of Directors of Expansion Therapeutics, Dr. Scott Rocklage, has helped the organization make advances in the attempt of finding a definitive cure for RNA related diseases. The founding investor of this company has been playing key roles in helping the organization raise adequate funding to support combat disorders arising from RNAs. The company added $55.3 million to the project while other related organizations also contributed. Some significant contributors to the cause include Sanofi, Norvatis, Kleiner Perkins and his very own 5 AM ventures.


Expansion Therapeutic has been working on medications that help treat illnesses that tend to get passed down, one generation to another. An example of this hereditary disorder is Myotonic Dystrophy. This condition is believed to be the world’s number one cause of muscle degeneration in adults. RNAs are the tiny molecules in our cells that are responsible for the production of proteins. The disorder that is Myotonic Dystrophy results when the output of these micro molecules, RNAs, reach toxic levels. In a report issued by the Chairman of the Board of Directors of Expansion Therapeutics, the doctor named Dr. Mathew Disney as the chief scientific researcher leading the project’s team.

Categories: Uncategorized